{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Study+arm&page=2", "query": { "intervention": "Study arm", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 30673, "total_pages": 3068, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Study+arm&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Study+arm&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-03T16:56:50.523Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02513394", "title": "PALbociclib CoLlaborative Adjuvant Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Palbociclib", "type": "DRUG" }, { "name": "Standard Adjuvant Endocrine Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance Foundation Trials, LLC.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5796, "start_date": "2015-08", "completion_date": "2028-12", "has_results": true, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-10-03T16:56:50.523Z", "location_count": 192, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 138 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02513394" }, { "nct_id": "NCT00314366", "title": "Intramyocardial Injection of Autologous Aldehyde Dehydrogenase-Bright Stem Cells for Therapeutic Angiogenesis (FOCUS Br)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Coronary Artery Disease" ], "interventions": [ { "name": "Stem Cell Therapy", "type": "BIOLOGICAL" }, { "name": "Control (plasma)", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Texas Heart Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 21, "start_date": "2006-04", "completion_date": "2023-08-24", "has_results": true, "last_update_posted_date": "2024-04-23", "last_synced_at": "2026-10-03T16:56:50.523Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00314366" }, { "nct_id": "NCT06228456", "title": "Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Coronary Artery Disease" ], "interventions": [ { "name": "Ticagrelor 60mg", "type": "DRUG" }, { "name": "Clopidogrel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2024-04-01", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-10-03T16:56:50.523Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06228456" }, { "nct_id": "NCT03968822", "title": "Intralipid® 20% for Reversal of Local Anesthetics", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Anesthesia, Local" ], "interventions": [ { "name": "Lidocaine 2%", "type": "DRUG" }, { "name": "Lidocaine 1%", "type": "DRUG" }, { "name": "Bupivacaine 0.25%", "type": "DRUG" }, { "name": "Bupivacaine 0.5%", "type": "DRUG" }, { "name": "Intralipid, 20% Intravenous", "type": "DRUG" }, { "name": "Saline intravenously", "type": "OTHER" }, { "name": "Saline", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Hospital for Special Surgery, New York", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2019-07-26", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2025-12-08", "last_synced_at": "2026-10-03T16:56:50.523Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03968822" }, { "nct_id": "NCT05946551", "title": "Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Cetirizine", "type": "DRUG" }, { "name": "Famotidine", "type": "DRUG" }, { "name": "Cetirizine Placebo", "type": "DRUG" }, { "name": "Famotidine Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2024-03-08", "completion_date": "2024-06-24", "has_results": true, "last_update_posted_date": "2025-07-17", "last_synced_at": "2026-10-03T16:56:50.523Z", "location_count": 4, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05946551" }, { "nct_id": "NCT06129851", "title": "Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage IIC Prostate Cancer AJCC v8", "Stage III Prostate Cancer AJCC v8", "Stage IV Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Brachytherapy", "type": "RADIATION" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Dual X-ray Absorptiometry", "type": "PROCEDURE" }, { "name": "External Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "PSMA PET Scan", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Relugolix", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "RADIATION", "OTHER", "DRUG" ], "sponsor": "University of Kansas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 90, "start_date": "2023-11-20", "completion_date": "2026-10-23", "has_results": false, "last_update_posted_date": "2023-11-13", "last_synced_at": "2026-10-03T16:56:50.523Z", "location_count": 1, "location_summary": "Kansas City, Kansas", "locations": [ { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06129851" }, { "nct_id": "NCT00052962", "title": "Debulking and Chemotherapy With or Without Intraperitoneal Chemotherapy to Treat Peritoneal Carcinomatosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastrointestinal Neoplasm" ], "interventions": [ { "name": "Cytoreductive surgery", "type": "PROCEDURE" }, { "name": "Continuous hyperthermic peritoneal perfusion (HIPEC/CHPP)", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2003-01", "completion_date": "2008-09", "has_results": true, "last_update_posted_date": "2012-11-22", "last_synced_at": "2026-10-03T16:56:50.523Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00052962" }, { "nct_id": "NCT02187861", "title": "A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Follicular Lymphoma" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 163, "start_date": "2014-12-01", "completion_date": "2018-03-16", "has_results": true, "last_update_posted_date": "2019-06-05", "last_synced_at": "2026-10-03T16:56:50.523Z", "location_count": 17, "location_summary": "Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 12 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Austell", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02187861" }, { "nct_id": "NCT07079670", "title": "Safety and Immunogenicity of NVX-CoV2705", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID-19", "SARS-CoV-2 Infection" ], "interventions": [ { "name": "NVX-CoV2705", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "12 Years to 90 Years" }, "enrollment_count": 676, "start_date": "2025-10-09", "completion_date": "2026-05-11", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-10-03T16:56:50.523Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Melrose Park, Illinois • Lenexa, Kansas + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Melrose Park", "state": "Illinois" }, { "city": "Lenexa", "state": "Kansas" }, { "city": "Lafayette", "state": "Louisiana" }, { "city": "Southfield", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT07079670" }, { "nct_id": "NCT05955183", "title": "Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 in Japanese and Chinese Healthy Volunteers..", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "AZD5055", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 38, "start_date": "2023-07-27", "completion_date": "2023-12-04", "has_results": false, "last_update_posted_date": "2023-12-08", "last_synced_at": "2026-10-03T16:56:50.523Z", "location_count": 1, "location_summary": "Glendale, California", "locations": [ { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05955183" } ] }